首页> 外文OA文献 >Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib

【2h】

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib

机译：达沙替尼治疗慢性相慢性骨髓白血病患者的长期安全性和疗效，耐药或不耐受伊马替尼

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Khalid Shoumariyeh; Nikolas von Bubnoff;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib [J] . Khalid Shoumariyeh, Nikolas von Bubnoff Blood and Lymphatic Cancer: Targets and Therapy . 2014,第2期

机译：达沙替尼治疗对伊马替尼耐药或不耐受的慢性慢性髓样白血病患者的长期安全性和有效性
2. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. [J] . Shah NP, Kantarjian HM, Kim DW, Journal of Clinical Oncology . 2008,第19期

机译：每天一次使用达沙替尼100 mg的间歇性靶抑制可保持疗效，并改善对伊马替尼耐药和不耐受的慢性慢性粒细胞白血病的耐受性。
3. Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia [J] . AbbottB.L. Clinical therapeutics . 2012,第2期

机译：达沙替尼：从对伊马替尼耐药或不耐受的慢性粒细胞白血病患者的治疗到新诊断的慢性期慢性粒细胞白血病患者的治疗
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib [O] . Oliver Ottmann, Giuseppe Saglio, Jane F. Apperley, 2018

机译：达沙替尼对伊马替尼耐药或不耐受的慢性髓性白血病加速期患者的长期疗效和安全性
7. Long-term efficacy and safety of dasatinib 100 mg once-daily (QD) in patients with imatinib-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP): 5-year follow-up from CA180-034 [O] . Brümmendorf, Tim Henrik, Shah, Nadim Joni, Cortes, J. E., 2011

机译：每天100 mg达沙替尼（QD）对伊马替尼耐药/不能耐受的慢性期慢性粒细胞白血病（CML-CP）患者的长期疗效和安全性：CA180-034起5年随访

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib

著录项

引文网络

相似文献

相关主题

期刊订阅